Published in Vaccine Weekly, September 24th, 2008
"The primary end points of the trial were safety and immune response to vaccine. Subjects were randomized to vaccine administered every other week...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.